ZHUZHOU, China, Oct. 22, 2024 /PRNewswire/ -- On the FIA TCR World Tour held in October 19-20, Lynk & Co Cyan Racing finished strong on podium again, with a winner's award and two third places, successfully secured the lead on the overall rankings.
Round 11 & 12 of the TCR World Tour took place at Zhuzhou International Circuit. The entire track has 14 turns, with a maximum height difference of 25.98 meters, creating an extreme test for the vehicle's performance, handling ability and the driver's skills. The severe thunderstorm during the race presented new challenges for the riders, created a high degree of uncertainty about the race.
Qualifying saw the Lynk & Co Cyan Racing team take the top three places, securing strong pole positions for the following races. Under rainy conditions in Round 1, dry tires and the Lynk & Co 03 FL's BoP weights were very restrictive, resulting in Thed Björk taking third place. In Round 2, Lynk & Co Cyan Racing's Ma Qing Hua made a great start to the race to move into second place, kept up the pressure and went on the attack on the last lap. He dived down the inside at T4, continued to tangle and made a daring move, winning at last by less than four tenths. Double world champion Yann Ehrlacher also performed well in this incident-packed race, finishing third on the podium despite facing technical issues.
It is worth noting that the Lynk & Co Teamwork Motorsport team, which competes in the TCR China series, has also demonstrated its leadership in these rounds. The team competed on the same track with Lynk & Co Cyan Racing, and continues to lead the TCR China driver and team standings.
The Lynk & Co 03 Series, as the racing models for both Lynk & Co teams, showcases race-level performance and outstanding quality, highlighting the brand's racing DNA. The brand continues to apply the experience and technology it has accumulated in major racing competitions to the design of mass-produced models, enriching the product experience with race-level tuning.
The results continue to defend Lynk & Co Cyan Racing's lead in the standings and provide the team with a solid foundation for the annual championship in Macau in November. Lynk & Co will continue to show the world the strength of the brand, empowering everyday drives with race-grade product performance, and continuing to change the mobility experience.
About Lynk & Co:
Launched in 2016, Lynk & Co is created for the new generation of open urbanites. Lynk & Co is not just a new car brand but a new brand in the car industry. Born global, open, and connected, the brand aims to build an open platform connecting people, cars, and the world.
Contact:
lynkco.media@lynkco.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Success on Podium: Lynk & Co Cyan Racing Wins the Race in Zhuzhou
Success on Podium: Lynk & Co Cyan Racing Wins the Race in Zhuzhou
Success on Podium: Lynk & Co Cyan Racing Wins the Race in Zhuzhou
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
